Cote d’Ivoire

DOLF NTDs Present in Cote d’Ivoire
LF Onchocerciasis Loa Loa STH


Analysis of MDA Frequency in Cote d’Ivoire
Optimization of Mass Drug Administration with Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Democratic Ivory Coast
Study Sites: Abengourou and Akoupe, Cote d’Ivoire

The objective of this study is to compare the treatment effect of MDA with Albendazole and Ivermectin delivered once per year to MDA delivered twice per year. The first follow-up evaluation was conducted in the summer of 2015 at two sites. Two further evaluations will be completed by the summer of 2017.

Randomized Trial of Albendazole Alone for LF in Cote d’Ivoire
LF Randomized Controlled Trial in Southern Cote d’Ivoire
Study Sites: Agboville, Cote d’Ivoire

This trial investigates the impact of treatment with Albendazole alone given annually and semi-annually on lymphatic filariasis. One arm of the study is also being treated with a triple drug regimen (Albendazole + Ivermectin + Diethylcarbamazine). This arm was added because of encouraging results with this regimen from Papua New Guinea. Subjects randomized to the triple drug regimen are screened for onchocerciasis by skin snip. Participants with positive skin snip results are excluded from the study.


Conventional parasitology and DNA-based diagostic methods for onchoceriasis elimination programmes
Acta Tropica 146 (2015) 114-118

Implementation Partners

Research Collaborator:
Programme National de Lutte Contre la Schistosomiase, les Giohelminthiases et la Filariose Lymphatique
Abidjan, Cote d’Ivoire
Dr. Aboulaye Meite, Coordinateur National

Coordinating Institution:
Center for Global Health & Disease, Case Western Reserve University
Cleveland, USA
Dr. James Kazura, Director
Dr. Christopher King, Professor of International Health

Translate »